Abstract
The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 111-123 |
| Number of pages | 13 |
| Journal | Diabetes Technology and Therapeutics |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Medicine (miscellaneous)
- Clinical Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Chronic intermittent intravenous insulin therapy : A new frontier in diabetes therapy. / Aoki, T. T.; Grecu, E. O.; Arcangeli, M. A.; Benbarka, M. M.; Prescott, Pamela T; Jong Ho Ahn, Ho Ahn.
In: Diabetes Technology and Therapeutics, Vol. 3, No. 1, 2001, p. 111-123.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chronic intermittent intravenous insulin therapy
T2 - A new frontier in diabetes therapy
AU - Aoki, T. T.
AU - Grecu, E. O.
AU - Arcangeli, M. A.
AU - Benbarka, M. M.
AU - Prescott, Pamela T
AU - Jong Ho Ahn, Ho Ahn
PY - 2001
Y1 - 2001
N2 - The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).
AB - The limited success achieved in controlling diabetes and its complications with conventional insulin therapy suggests the need for reevaluation of the appropriateness of insulin administration protocols. Indeed, conventional subcutaneous insulin administration produces slowly changing blood insulin levels and suboptimal hepatocyte insulinization resulting in impaired hepatic capacity for processing incoming dietary glucose. The novel approach to insulin administration known as chronic intermittent intravenous insulin therapy (CIIIT) delivers insulin in a pulsatile fashion and achieves physiological insulin concentration in the portal vein. Done as a weekly outpatient procedure combined with daily intensive subcutaneous insulin therapy, this procedure has been shown to (1) significantly improve glycemic control while decreasing the incidence of hypoglycemic events, (2) improve hypertension control, (3) slow the progression of overt diabetic nephropathy, and (4) reverse some manifestations of diabetic autonomic neuropathy (e.g., abnormal circadian blood pressure pattern, severe postural hypotension, and hypoglycemia unawareness).
UR - http://www.scopus.com/inward/record.url?scp=0035036261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035036261&partnerID=8YFLogxK
U2 - 10.1089/152091501750220073
DO - 10.1089/152091501750220073
M3 - Article
C2 - 11469701
AN - SCOPUS:0035036261
VL - 3
SP - 111
EP - 123
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
SN - 1520-9156
IS - 1
ER -